A Study Comparing Efficacy and Tolerance of Two Maintenance Strategies : a Monotherapy With Lopinavir/Ritonavir or a Single-tablet Triple Therapy by Efavirenz/Emtricitabin/Tenofovir in HIV-1 Infected Patients With HIV RNA Below 50 cp/mL.

Trial Profile

A Study Comparing Efficacy and Tolerance of Two Maintenance Strategies : a Monotherapy With Lopinavir/Ritonavir or a Single-tablet Triple Therapy by Efavirenz/Emtricitabin/Tenofovir in HIV-1 Infected Patients With HIV RNA Below 50 cp/mL.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms DREAM
  • Most Recent Events

    • 26 Jul 2017 Results (n=637) of pooled analysis of NCT00140751, NCT00421551, NCT00946595 trials analysing distribution of ultrasensitive viral load (USVL) and impact of USVL on virological failure presented at the 9th International AIDS Society Conference on HIV Science
    • 10 Jun 2017 Biomarkers information updated
    • 23 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top